Clinical Trials
7 trialsNCT04986423 2026-05-08
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics
Phase 2 Recruiting
NCT07287150 2026-05-06
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT03414034 2024-11-07
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Cardiff Oncology
Phase 2 Completed
NCT04408924 2024-06-25
CYCLONE 1
Eli Lilly and Company
Phase 2 Completed
NCT04419402 2024-02-07
ENZA-p
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT02125357 2020-08-07
Sequencing Abiraterone and Enzalutamide in mCRPC
British Columbia Cancer Agency
Phase 2 Completed
NCT02091531 2019-11-21
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed